Quote | Black Diamond Therapeutics Inc. (NASDAQ:BDTX)
Last: | $4.535 |
---|---|
Change Percent: | 1.45% |
Open: | $4.47 |
Close: | $4.47 |
High: | $4.58 |
Low: | $4.445 |
Volume: | 26,745 |
Last Trade Date Time: | 07/08/2024 03:00:00 am |
News | Black Diamond Therapeutics Inc. (NASDAQ:BDTX)
2024-06-27 10:38:07 ET Summary Black Diamond Therapeutics, Inc. is developing a next-generation EGFR inhibitor with promising early data in lung cancer. BDTX-1535 targets EGFR mutations, especially resistance drivers, with key data readouts expected in 2024 and early 2025. Bla...
2024-06-17 20:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Message Board Posts | Black Diamond Therapeutics Inc. (NASDAQ:BDTX)
Subject | By | Source | When |
---|---|---|---|
$BDTX: See UP-dated 'Chart', below!!! | Invest-in-America | investorshub | 06/27/2023 5:21:25 PM |
$BDTX: See the 'CHART', right now, below!!! | Invest-in-America | investorshub | 06/27/2023 5:00:37 PM |
$BDTX: Are you feelin' LUCKY?? Bet your damn | Invest-in-America | investorshub | 06/27/2023 4:54:31 PM |
Wild | Awl416 | investorshub | 06/27/2023 4:31:02 PM |
$BDTX: Hey, Mr. dcaf7, I'm tryin' to get | Invest-in-America | investorshub | 06/27/2023 4:22:45 PM |
News, Short Squeeze, Breakout and More Instantly...
Black Diamond Therapeutics Inc. Company Name:
BDTX Stock Symbol:
NASDAQ Market:
Black Diamond Therapeutics Inc. Website:
2024-06-17 20:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging anti-tumor activity and duration of treatment Initial data from Phase 0/1 “trigger” (“window of opportunity”) inves...
CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced that its Chief Executive Officer, Mark Vell...